Ten years ago, Acadia Pharmaceuticals had one approved drug, a stock that had just doubled on FDA news, and no clear path to profit. Today it has two commercial products generating more than a billion dollars a year, a net margin that would make most pharmaceutical companies envious, and a stock priced as though the improvement is already over. Those two facts should not coexist, and the gap between them is the story.
The heart of it
The math, meaning what the filed numbers actually show, is a company that swung from losing money on every dollar of sales to keeping more than a third of each one, in roughly three years. The mood, meaning what the market is currently paying, values Acadia at a price-to-earnings multiple that sits in the bottom fifth of its own decade-long range. The open question is whether the market is correctly pricing a business whose growth is slowing, or whether it is discounting a profitable, cash-rich company as if the old losses still define it.
How a decade of losses became a margin story
Acadia spent most of its life as a company that burned cash in pursuit of a single bet: pimavanserin, a drug for the hallucinations that haunt Parkinson’s disease patients. When the FDA approved Nuplazid in April 2016, the stock surged, but the profits did not follow immediately. The drug sold well enough to keep the lights on, yet the company kept spending heavily on expanding the label and building a pipeline, and the losses mounted. By the end of 2020, as the 10-K for fiscal year 2024 shows in retrospect, the company was spending well over a dollar for every dollar it brought in.
The turning point was not Nuplazid growing faster. It was a second drug entirely. In March 2023, the FDA approved Daybue (trofinetide) as the first-ever treatment for Rett syndrome, a rare neurological condition that robs children, mostly girls, of speech and motor control. That approval changed Acadia’s financial character. Revenue jumped sharply in 2023, and the company posted its first profitable year in FY2024, when net income turned positive for the first time. By fiscal year 2025, revenue had reached $1.07 billion and the net margin had expanded to 36.5%, meaning more than a third of every sales dollar was falling to the bottom line. That is a faster margin expansion than most drug companies achieve in a decade, compressed into three years.
The analytical question is whether that margin is real and durable, or a temporary artifact of a launch cycle.
What the most recent quarter actually shows
The 10-Q for the quarter ended June 30, 2026 is the freshest evidence. Total revenues were $308 million, up meaningfully from the same quarter a year earlier. Nuplazid contributed the larger share, growing at a steady single-digit pace on solid volume gains, with new patient prescriptions up sharply. Daybue contributed the remainder, growing roughly three times as fast as Nuplazid, driven almost entirely by volume rather than price increases.
The gross margin for the quarter was roughly 91%, which means that for every dollar Acadia collected from pharmacies and insurers, it spent about nine cents making and delivering the product. That is a characteristic of drug businesses with established manufacturing: the marginal cost of one more pill is nearly zero. What eats into that margin is the selling and administrative machinery, and the research pipeline, leaving net income of $32 million for the quarter.
The cash position is the other figure worth holding: $956 million in cash and investment securities as of June 30, 2026, against $550 million in senior notes that do not come due until 2033. A company carrying nearly twice its debt in liquid assets is not a company under financial pressure. That matters because the next chapter of Acadia’s story, the Alzheimer’s drug remlifanserin, will cost money to run through trials, and the balance sheet says it can afford to find out.
The crowded trade hiding in plain sight
Here is where the mood diverges sharply from the math. Our data shows Acadia’s price-to-earnings multiple, the price tag per dollar of annual profit, sitting at 12.3 times. The median for this same stock over the past decade is 18.7 times. The current reading lands in the 19th percentile of its own history, meaning the stock has traded cheaper than this only about one year in five over the past decade, and during most of those cheaper periods the company was losing money.
The price-to-sales multiple tells a similar story: well below the decade median, sitting in the lower third of its historical range. The market is not paying up for this business despite the fact that the business is more profitable than it has ever been.
Published analyst price targets as of September 2026, sourced from Stock Analysis and MarketBeat, span a wide range, from roughly $15 on the cautious end to $49 on the optimistic end, reflecting divergent assumptions about pipeline outcomes rather than disagreement about filed quarterly results. The spread itself is the analytical signal: where an observer lands within that range depends almost entirely on what probability one assigns to remlifanserin and to Daybue’s long-run ceiling, neither of which the filed numbers resolve. IF, for instance, earnings were to hold at current levels and the multiple were to revert toward the decade median of 18.7 times, the implied price would differ substantially from outcomes in which profits contract or the pipeline disappoints.
That wide spread suggests the disagreement is not about this quarter’s numbers, which are publicly filed, but about what happens next, making the filed numbers a more reliable starting point than averaged opinions.
What the numbers cannot tell us
The honest limit of this analysis is the pipeline. Acadia’s current valuation discount may be rational if the market believes Nuplazid and Daybue are near their commercial ceilings and nothing replaces them. Nuplazid’s growth is slowing to single digits. Daybue is growing fast but serves a rare disease population that is, by definition, finite. The European Commission granted marketing authorization for Daybue on August 24, 2026, opening a new geography, but European rare disease launches tend to be slower than U.S. ones.
Remlifanserin, the Alzheimer’s psychosis drug that received FDA Fast Track designation in July 2026, is the variable that no filed number can resolve. Topline Phase 2 results are expected in the autumn of 2026, meaning they may land within weeks of this article. Alzheimer’s disease psychosis affects millions of people, a population orders of magnitude larger than Rett syndrome. If the data are positive, the addressable market changes the conversation entirely. If they are not, the growth story rests on two maturing drugs. The filed numbers are silent on which outcome arrives.
What the numbers do say is that Acadia enters that binary moment in better financial shape than at any point in its history, with nearly a billion dollars in liquid assets and a business generating real profit. That is a different posture than the company that spent years burning cash on a single drug and hoping.
Reading the numbers
- Net margin, FY2025: 36.5%. This is the share of each sales dollar left after every cost, from manufacturing to executive salaries to interest on debt. A household analogy: if a family earned $100,000 and spent $63,500 on everything, $36,500 would be left over. Three years ago this number was negative. The speed of the improvement is the unusual thing.
- Q2 2026 gross margin: ~91%. Gross margin strips out only the direct cost of making the product, not the sales force or research. For Acadia, it costs roughly nine cents to manufacture and deliver a dollar’s worth of drug. That is typical of established branded pharmaceuticals with no generic competition. It means almost all of the revenue is available to fund research and profit, before the sales machinery takes its cut.
- P/E multiple: 12.3 times, against a decade median of 18.7 times. A P/E multiple is the price tag per dollar of annual earnings. At 12.3 times, a buyer of the stock today is paying $12.30 for each dollar of annual profit the company generates. The same stock, at its historical median, would cost $18.70 per profit dollar. The gap implies either the market expects profits to shrink, or the stock is priced below what its own history suggests is normal for this business at this level of profitability.
- Cash position: $956 million vs. $550 million in debt. Think of it as a household with $95,600 in savings and a $55,000 mortgage that does not come due for seven years. The household is not in financial distress. It can afford to take on a large project, in Acadia’s case a Phase 3 trial, without needing to borrow more.
- Revenue growth rate: 11.9% in FY2025, down from 31.8% in FY2024. Growth is decelerating, which is normal as a drug moves from launch into steady-state. The question the market is pricing is whether 10% to 15% growth is the new ceiling or a temporary plateau before a pipeline drug opens a new chapter.
Sources
- 10-Q for quarter ended June 30, 2026 (SEC EDGAR)
- 10-K for fiscal year ended December 31, 2025 (SEC EDGAR)
- 10-K for fiscal year ended December 31, 2024 (SEC EDGAR)
- Acadia Q2 2026 earnings press release
- FDA approval of Nuplazid, April 2016 (Acadia press release)
- Acadia 8-K material events, including EC authorization and Fast Track designation (Webull/SEC)
- Analyst consensus and price targets, September 2026 (Stock Analysis)
- MarketBeat analyst consensus, August 25, 2026
